Propanc Biopharma, Inc., a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced that the Company’s board of directors has approved a reverse stock split of its common stock at a ratio of 1 post-split share for every 1,000 pre-split shares.
